Badier M, Beaumont D, Orehek J
Institut National de la Santé et de la Recherche Medicale Unité, Marseille, France.
J Allergy Clin Immunol. 1988 Feb;81(2):437-40. doi: 10.1016/0091-6749(88)90913-x.
The effect of terfenadine, a selective H1-receptor antagonist devoid of central nervous system side effects, was evaluated on hyperventilation-induced bronchospasm in 11 adult subjects with asthma in a double-blind, placebo-controlled, crossover study. Increases in specific airway resistance (SRaw) were induced by isocapnic hyperventilation with dry air on two occasions, 7 days apart. Before the tests, the subjects received oral terfenadine (120 mg, twice daily) or placebo for 3 days with the last dose administered 3 hours before the test. Baseline SRaw and spirometric values (vital capacity and FEV1) were similar for the two tests. Terfenadine yielded a significant (p less than 0.001) parallel shift to the right of the stimulus (hyperventilation)-response (SRaw) curve; 100% increases in SRaw occurred at ventilation rates of 44 L/min after placebo treatment and 64 L/min after terfenadine treatment. These data suggest that histamine release plays a role in hyperventilation-induced bronchospasm despite the fact that increase in plasma histamine has not been found in this situation, in contrast to exercise-induced bronchospasm.
在一项双盲、安慰剂对照、交叉研究中，对11名成年哮喘患者，评估了特非那定（一种无中枢神经系统副作用的选择性H1受体拮抗剂）对过度通气诱发的支气管痉挛的作用。在两次间隔7天的情况下，用干燥空气进行等碳酸过度通气诱发气道比传导率（SRaw）增加。在测试前，受试者口服特非那定（120毫克，每日两次）或安慰剂3天，最后一剂在测试前3小时服用。两次测试的基线SRaw和肺量计值（肺活量和第一秒用力呼气量）相似。特非那定使刺激（过度通气）-反应（SRaw）曲线显著（p<0.001）平行右移；安慰剂治疗后，在通气率为44升/分钟时SRaw增加100%，特非那定治疗后在通气率为64升/分钟时SRaw增加100%。这些数据表明，尽管在这种情况下未发现血浆组胺增加，与运动诱发的支气管痉挛相反，但组胺释放仍在过度通气诱发的支气管痉挛中起作用。
